TerminatedPhase 3

Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

Stopped: business reasons

United States408 participantsStarted 2006-03

Plain-language summary

The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diabetes type 1 or 2 * Painful symptoms of diabetic neuropathy in the lower extremities extremities for at least 6 months Exclusion Criteria: * Major Depression * Uncontrolled diabetes

What they're measuring

Change in Mean Pain Severity Score From Baseline to 13 Weeks

Timeframe: Baseline and 13 weeks

Trial details

NCT IDNCT00283842

SponsorWyeth is now a wholly owned subsidiary of Pfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-06

Results submitted2009-06-30

View on ClinicalTrials.gov More Diabetic Neuropathies trials